AstraZeneca Pharma India, a drug firm, has announced that it received green signal from Drug Controller General of India (DCGI) to import and market olaparib tablets.
The tablets are used to treat patients suffered with ovarian and breast cancer.
DCGI gave its go-ahead for olaparib (Lynparza) tablets in the strengths of 100 mg and 150 mg, AstraZeneca Pharma India said in a BSE filing.
The tablets are a patented product of the AstraZeneca group, it added.
Responding to the development, Gagan Singh, Managing Director, AstraZeneca Pharma India, said, “The import and market permission for olaparib is a significant milestone for women in India living with platinum-sensitive relapsed ovarian cancer and BRCA-mutated HER-2 negative metastatic breast cancer, which has historically been difficulty-to-treat diseases.”
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
